Metabolism, excretion and pharmacokinetics of a single dose of [<sup>14</sup>C]-raltitrexed in cancer patients
Authors: Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. and Walker, M.
Journal: Cancer Chemotherapy and Pharmacology
Volume: 42
Issue: 1
Pages: 71-76
ISSN: 0344-5704
DOI: 10.1007/s002800050787
Abstract:Raltitrexed (Tomudex) is a specific inhibitor of thymidylate synthase and has recently been licensed in Europe for use in the treatment of advanced colorectal carcinoma. This study evaluated the metabolism, excretion and pharmacokinetics after a single dose of 3.0 mg/m2 [14C]-raltitrexed in patients with advanced solid malignancies not amenable to curative therapy. From April 1994 to July 1995, nine patients (six men and three women) were recruited into the study. Pharmacokinetics analysis was performed during the first cycle of treatment in all patients and, in two patients, limited sampling was done prior to and during the second cycle of treatment. The mean observed peak plasma concentration (C(max)) was 700.6 ng/ml and the median time (t(max)) to reach maximal raltitrexed concentrations was 15 min after the initiation of the infusion. After reaching C(max) the drug declined in a triexponential manner with a terminal half-life of 257 h. The AUC(0-∞) as predicted by the pharmacokinetic model was 2341.7 ng h ml-1. Clearance was 41.3 ml/min, of which renal clearance accounted for 50-60%. Urinary collection for the measurement of radiolabeled drug revealed that renal excretion estrapolated to infinity accounted for 40% of the total radioactive dose. Faecal excretion accounted for only 3% of the dose when samples were collected to day 5 in the first six patients. Collection was extended to 10 days in the last three patients and faecal elimination accounted for 14% in these patients. Raltitrexed measurements prior to subsequent doses suggest that there was no accumulation of the drug with repeated administration. Low levels of radioactivity measured in the red cell pellets on days 15, 22 and 29 are likely to represent drug retained by newly forming red cells at the time of dosing. Examination of the urine revealed that the drug was excreted unchanged. The toxicities seen were in line with those encountered in previous studies. Grade 3 and 4 thrombocytopenia occurred in three patients and grade 3 neutropenia occurred in two patients.
Source: Scopus
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Authors: Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. and Walker, M.
Journal: Cancer Chemother Pharmacol
Volume: 42
Issue: 1
Pages: 71-76
ISSN: 0344-5704
DOI: 10.1007/s002800050787
Abstract:Raltitrexed (Tomudex) is a specific inhibitor of thymidylate synthase and has recently been licensed in Europe for use in the treatment of advanced colorectal carcinoma. This study evaluated the metabolism, excretion and pharmacokinetics after a single dose of 3.0 mg/m2 [14C]-raltitrexed in patients with advanced solid malignancies not amenable to curative therapy. From April 1994 to July 1995, nine patients (six men and three women) were recruited into the study. Pharmacokinetics analysis was performed during the first cycle of treatment in all patients and, in two patients, limited sampling was done prior to and during the second cycle of treatment. The mean observed peak plasma concentration (Cmax) was 700.6 ng/ml and the median time (tmax) to reach maximal raltitrexed concentrations was 15 min after the initiation of the infusion. After reaching Cmax the drug declined in a triexponential manner with a terminal half-life of 257 h. The AUC0-infinity as predicted by the pharmacokinetic model was 2341.7 ng h ml(-1). Clearance was 41.3 ml/min, of which renal clearance accounted for 50-60%. Urinary collection for the measurement of radiolabeled drug revealed that renal excretion extrapolated to infinity accounted for 40% of the total radioactive dose. Faecal excretion accounted for only 3% of the dose when samples were collected to day 5 in the first six patients. Collection was extended to 10 days in the last three patients and faecal elimination accounted for 14% in these patients. Raltitrexed measurements prior to subsequent doses suggest that there was no accumulation of the drug with repeated administration. Low levels of radioactivity measured in the red cell pellets on days 15, 22 and 29 are likely to represent drug retained by newly forming red cells at the time of dosing. Examination of the urine revealed that the drug was excreted unchanged. The toxicities seen were in line with those encountered in previous studies. Grade 3 and 4 thrombocytopenia occurred in three patients and grade 3 neutropenia occurred in two patients.
Source: PubMed
Preferred by: Tamas Hickish
Metabolism, excretion and pharmacokinetics of a single dose of [<SUP>14</SUP>C]-raltitrexed in cancer patients
Authors: Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. and Walker, M.
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume: 42
Issue: 1
Pages: 71-76
ISSN: 0344-5704
DOI: 10.1007/s002800050787
Source: Web of Science (Lite)
Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Authors: Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. and Walker, M.
Journal: Cancer chemotherapy and pharmacology
Volume: 42
Issue: 1
Pages: 71-76
eISSN: 1432-0843
ISSN: 0344-5704
DOI: 10.1007/s002800050787
Abstract:Raltitrexed (Tomudex) is a specific inhibitor of thymidylate synthase and has recently been licensed in Europe for use in the treatment of advanced colorectal carcinoma. This study evaluated the metabolism, excretion and pharmacokinetics after a single dose of 3.0 mg/m2 [14C]-raltitrexed in patients with advanced solid malignancies not amenable to curative therapy. From April 1994 to July 1995, nine patients (six men and three women) were recruited into the study. Pharmacokinetics analysis was performed during the first cycle of treatment in all patients and, in two patients, limited sampling was done prior to and during the second cycle of treatment. The mean observed peak plasma concentration (Cmax) was 700.6 ng/ml and the median time (tmax) to reach maximal raltitrexed concentrations was 15 min after the initiation of the infusion. After reaching Cmax the drug declined in a triexponential manner with a terminal half-life of 257 h. The AUC0-infinity as predicted by the pharmacokinetic model was 2341.7 ng h ml(-1). Clearance was 41.3 ml/min, of which renal clearance accounted for 50-60%. Urinary collection for the measurement of radiolabeled drug revealed that renal excretion extrapolated to infinity accounted for 40% of the total radioactive dose. Faecal excretion accounted for only 3% of the dose when samples were collected to day 5 in the first six patients. Collection was extended to 10 days in the last three patients and faecal elimination accounted for 14% in these patients. Raltitrexed measurements prior to subsequent doses suggest that there was no accumulation of the drug with repeated administration. Low levels of radioactivity measured in the red cell pellets on days 15, 22 and 29 are likely to represent drug retained by newly forming red cells at the time of dosing. Examination of the urine revealed that the drug was excreted unchanged. The toxicities seen were in line with those encountered in previous studies. Grade 3 and 4 thrombocytopenia occurred in three patients and grade 3 neutropenia occurred in two patients.
Source: Europe PubMed Central